NASDAQ:VVOS

Vivos Therapeutics - VVOS Stock Forecast, Price & News

$0.65

-0.11 (-14.48%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.60
▼
$0.86
50-Day Range: $0.65
▼
$1.41
52-Week Range: $0.60
▼
$4.27

Volume: 175,870 shs
Average Volume: 34,503 shs
Market Capitalization: $14.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Vivos Therapeutics MarketRank™ Forecast

Analyst Rating: N/A
0.00 Rating Score
Upside/Downside: 669.3% Upside
$5.00 Price Target
Short Interest: Healthy
0.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.57
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.00) to ($0.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

907th out of 1,095 stocks

Surgical & Medical Instruments Industry

91st out of 106 stocks

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Vivos Therapeutics has a forecasted upside of 669.3% from its current price of $0.65.
Amount of Analyst Coverage
Vivos Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.79% of the float of Vivos Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Vivos Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vivos Therapeutics has recently decreased by 20.88%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Vivos Therapeutics does not currently pay a dividend.
Dividend Growth
Vivos Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VVOS.

2.0

News and Social Media Coverage

News Sentiment
Vivos Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Vivos Therapeutics this week, compared to 1 article on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vivos Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.60% of the stock of Vivos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 9.47% of the stock of Vivos Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Vivos Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vivos Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vivos Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vivos Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vivos Therapeutics (NASDAQ:VVOS) Stock

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VVOS Stock News Headlines

August 26, 2022 | finance.yahoo.com

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

August 22, 2022 | finance.yahoo.com

Vivos Therapeutics Provides Update on Second Quarter Earnings Delay

August 15, 2022 | finance.yahoo.com

Vivos Therapeutics to Reschedule Second Quarter 2022 Financial Results Conference Call

August 9, 2022 | finance.yahoo.com

Vivos Therapeutics Schedules Second Quarter 2022 Financial Results Conference Call

August 9, 2022 | finance.yahoo.com

Vivos Therapeutics Schedules Second Quarter 2022 Financial Results Conference Call

July 14, 2022 | nasdaq.com

Vivos Therapeutics' Entire Line Of Oral Appliances Gets Regulatory Approval In Australia

June 29, 2022 | seekingalpha.com

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

June 29, 2022 | finance.yahoo.com

Vivos Therapeutics Announces Exclusive Distribution Agreement with GM Instruments, Ltd. for the U.S. and Canada

June 14, 2022 | finance.yahoo.com

Vivos Therapeutics’ SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea

May 26, 2022 | finance.yahoo.com

Vivos Therapeutics to Present at Upcoming SLEEP 2022 Annual Meeting

May 21, 2022 | finance.yahoo.com

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Just Slashed This Year's Estimates

May 17, 2022 | seekingalpha.com

Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q1 2022 Results - Earnings Call Transcript

May 16, 2022 | seekingalpha.com

Vivos Therapeutics GAAP EPS of -$0.26 in-line, revenue of $3.46M misses by $0.98M

May 16, 2022 | finance.yahoo.com

Vivos Therapeutics Reports First Quarter 2022 Financial Results and Operational Update

April 28, 2022 | finance.yahoo.com

Vivos Therapeutics Schedules First Quarter 2022 Financial Results Conference Call

April 26, 2022 | finance.yahoo.com

Vivos Therapeutics Opens Third U.S. Multidisciplinary Center to Treat Patients Suffering from Sleep Apnea with The Vivos Method

March 31, 2022 | finance.yahoo.com

Vivos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

March 31, 2022 | seekingalpha.com

Vivos Therapeutics GAAP EPS of -$0.96, revenue of $16.89M

March 31, 2022 | finance.yahoo.com

Vivos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

March 31, 2022 | finance.yahoo.com

Vivos Therapeutics Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call

March 8, 2022 | benzinga.com

Fast Company Selects Vivos Therapeutics for 2022 "World's Most Innovative Companies" List

March 8, 2022 | finance.yahoo.com

Fast Company Selects Vivos Therapeutics for 2022 “World’s Most Innovative Companies” List

March 3, 2022 | finance.yahoo.com

Vivos Therapeutics Rebrands Proprietary Clinical Protocol for Treating Patients with Breathing and Sleep Disorders

March 2, 2022 | finance.yahoo.com

Vivos Therapeutics to Participate in Upcoming Investor Conferences

February 24, 2022 | finance.yahoo.com

Vivos Therapeutics to Present at March 2022 World Sleep Congress in Rome

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VVOS Company Calendar

Last Earnings: 11/15/2021
Today: 10/02/2022
Next Earnings (Estimated): 11/21/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VVOS
CUSIP: N/A
CIK: 1716166
Web: www.vivoslife.com
Phone: 866 908 4867
Fax: N/A
Employees: 147
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +669.3%
Consensus Rating: N/A
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.05)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,290,000.00
Net Margins: -132.59%
Pretax Margin: -120.15%
Return on Equity: -87.72%
Return on Assets: -66.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.64
Quick Ratio: 3.64

Sales & Book Value

Annual Sales: $16.89 million
Price / Sales: 0.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.11 per share
Price / Book: 0.59

Miscellaneous

Outstanding Shares: 23,010,000
Free Float: 20,343,000
Market Cap: $14.95 million
Optionable: Not Optionable
Beta: 0.88

Key Executives

Mr. R. Kirk Huntsman (Age 64)
Co-Founder, Chairman & CEO
Comp: $506.85k

Mr. Bradford K. Amman (Age 60)
CFO, Treasurer & Sec.
Comp: $300.53k

Mr. Todd Huntsman
Co-Founder & Sr. VP of Product and Technology

Ms. RaeAnn Byrnes
Co-Founder and Sr. VP of Events & Clinical Advisory Services

Ms. Susan McCullough
Co-Founder & Exec. VP

Ms. Julie Gannon
Chief of Staff & Investor Relations

Mr. George A. Gardiner
Sr. VP of Sales

Mr. Nicholas M. DeGennaro
Sr. VP of the Medical Integration Division

Ms. Ruth Hembree
Sr. VP of Practice Services

Ms. Stephanie Huebner
Sr. VP of DSO Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VVOS Stock - Frequently Asked Questions

What is Vivos Therapeutics' stock price forecast for 2022?: 0 analysts have issued twelve-month price objectives for Vivos Therapeutics' stock. Their VVOS share price forecasts range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 669.3% from the stock's current price.
View analysts price targets for VVOS or view top-rated stocks among Wall Street analysts.
How have VVOS shares performed in 2022?: Vivos Therapeutics' stock was trading at $2.25 at the start of the year. Since then, VVOS stock has decreased by 71.1% and is now trading at $0.6499.
View the best growth stocks for 2022 here.
When is Vivos Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our VVOS earnings forecast.
How were Vivos Therapeutics' earnings last quarter?: Vivos Therapeutics, Inc. (NASDAQ:VVOS) issued its earnings results on Monday, November, 15th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.10. The firm had revenue of $4.55 million for the quarter, compared to the consensus estimate of $4.50 million. Vivos Therapeutics had a negative net margin of 132.59% and a negative trailing twelve-month return on equity of 87.72%.

When did Vivos Therapeutics IPO?: (VVOS) raised $20 million in an IPO on Friday, December 11th 2020. The company issued 3,300,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.
What is Vivos Therapeutics' stock symbol?: Vivos Therapeutics trades on the NASDAQ under the ticker symbol "VVOS."
How do I buy shares of Vivos Therapeutics?: Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vivos Therapeutics' stock price today?: One share of VVOS stock can currently be purchased for approximately $0.65.
How much money does Vivos Therapeutics make?: Vivos Therapeutics (NASDAQ:VVOS) has a market capitalization of $14.95 million and generates $16.89 million in revenue each year. The company earns $-20,290,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.
How many employees does Vivos Therapeutics have?: The company employs 147 workers across the globe.
How can I contact Vivos Therapeutics?: The official website for the company is www.vivoslife.com. The company can be reached via phone at 866 908 4867 or via email at jgannon@vivoslife.com.

This page (NASDAQ:VVOS) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vivos Therapeutics - VVOS Stock Forecast, Price & News

Vivos Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Vivos Therapeutics (NASDAQ:VVOS) Stock

VVOS Stock News Headlines

VVOS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VVOS Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™